메지온

140410KOSDAQView the 바이오 R&D sectorTheme Bio & healthcare

59,800KRWMarket close of 10/21 (Wed)

Up +1.87%+1,100KRWMarket close of 10/21 (Wed)

Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/22 (Thu)57,500KRWDown -3.85%

Preliminary · just after the close · replaced by official KRX data tomorrow morning

Open
58,800
High
60,600
Low
58,800
Day range
Day range low 58,800 high 60,600, open 58,800, close 59,800, previous close 58,700
Volume
5×10K shares
3.1B KRW 0.41× the 20-session average

Market close of 10/21 (Wed)

Where it sits in the 1-year range

1-year close range 51,000 to 172,700 won, 7% up from the low

7% of the way up from the lowest close in 1 year (252 sessions) · -65.4% from the high

Something to check

1 to check: operating loss

Free · no sign-inSource from 2021-05-17

Points to check

  • Earningsto check-18.8B KRWOperating income over the last four quarters -18.8B KRW (loss)Operating income, 8 quarters
  • Daily moveusual range+1.87%+1.87%, 0.5× the usual (20-session average ±3.49%)
    That day +1.87% · usual ±3.49% · large-move threshold ±7.0%
  • Trading valueusual range0.4×3.1B KRW, 0.4× the 20-session average
    0.41× the 20-session average · check threshold 3×

The other 3 are within the usual range

  • Recent filings0Last 14 days
  • Foreign & institutional+200.00 million KRWusual range
  • Data date10/21 (Wed)Market close
See the full check report

Same sector · 바이오 R&D

Up +3.03%

· 33 of 64 stocks up, preferred shares excluded · trading value 215.2B KRW

Same sector · top by trading value
Stock20DChangeTrading value
알테오젠Close over the last 20 sessions -5.5%Up +3.90%60.7B KRW
올릭스Close over the last 20 sessions -6.4%Up +9.53%26.1B KRW
디앤디파마텍Close over the last 20 sessions -6.0%Up +6.65%22.0B KRW
리가켐바이오Close over the last 20 sessions -14.3%Up +2.00%12.9B KRW
프로티나Close over the last 20 sessions +35.7%Up +7.23%11.0B KRW

Schedule

  • Q3 report due · 11/16 (Mon) · in 24 days
  • Next data 10/23 (Fri) after 08:50

For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.